NCT03659448 - Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions

Colorectal Neoplasms

Interventions

DRUG

SGM-101

A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.

Trial Locations (11)

3015

RECRUITING

Erasmus MC, Rotterdam

19104

RECRUITING

Perelman Center for Advanced Medicine, Philadelphia

27100

RECRUITING

Fondazione IRCCS Policlinico San Matteo, Pavia

33331

RECRUITING

Cleveland Clinic Florida, Weston

37075

RECRUITING

Universitätsmedizin Göttingen, Klinik für Allgemein- Viszeral- und Kinderchirurgie, Göttingen

91010

RECRUITING

City of Hope National Medical Center, Duarte

92093

RECRUITING

Moores Cancer Center - UCSD Health, La Jolla

02114

NOT_YET_RECRUITING

Massachusetts General Hospital, Boston

01655

RECRUITING

University of Massachusetts, Worcester

Unknown

RECRUITING

Catharina Ziekenhuis Eindhoven, Eindhoven

2333 CL

RECRUITING

Leiden University Medical Center, Leiden